Delivery Order SPE2DB22D2007-SPE2DB25FJ3HE
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $9,584.58 to supply Trodelvy 180 mg vials, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 5, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in...
- The Defense Logistics Agency's Medical Supply Chain awarded a $9,584.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Trodelvy 180 mg vials, with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026....
- The Defense Logistics Agency awarded a $6,389.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Trodelvy 180 mg vials, with an ultimate completion date of August 25, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a $9,584.58 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Trodelvy 180 mg vials. The award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This delivery order was competitively awarded without a set-aside...
- The Defense Logistics Agency awarded a $9,584.58 delivery order to AmerisourceBergen Drug Corp for the supply of Trodelvy 180 mg vials, with a completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order reflects the pharmaceutical distributor's ongoing role as a critical medical supplier to federal healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Trodelvy 180 mg vials, a medication used in the treatment of certain types of cancer. The contract has a ceiling value of $3,194.86 and a completion date of July 25, 2025. It is a firm-fixed-price contract, with no set-aside designation, indicating open competition....
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 180 mg vials of the specialty pharmaceutical drug Trodelvy. The contract has a ceiling value of $9,010.50 and a period of performance through April 1, 2024. This delivery order is issued under a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp with a potential value of $999,999,999.00...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Trodelvy 180 mg vials. The contract has a ceiling value of $6,389.72 and a performance period ending on May 22, 2025. It is a firm fixed-price contract, and there is no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The U.S. Defense Logistics Agency (DLA) awarded a $12,014 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of 180 mg vials of the drug TRODELVY. This delivery order falls under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with the DLA Troop Support Medical, which provides a comprehensive range of medical commodities to support military treatment programs and facilities worldwide....
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $18,021.00 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the pharmaceutical product TRODELVY 180 MG VIALS. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through December 31, 2025. The IDC serves as the primary...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3HEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Trodelvy 180 mg vials with a ceiling value of $9,584.58. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a broad portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Trodelvy (sacituzumab govitecan) is a targeted cancer therapy, reflecting the company's role in providing specialized pharmaceutical products across multiple therapeutic domains to support military medicine. The DLA Troop Support Medical contract structure enables flexible fulfillment of federal medical supply needs while positioning AmerisourceBergen among multiple vendors expected to serve under the planned Pharmaceutical Prime Vendor Global Program Generation V contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.6k | 7/24/25 |